These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32163180)

  • 41. [Clinical courses and risk factors for progression of smoldering multiple myeloma: a nationwide cohort study in Japan].
    Takamatsu Y; Muta T
    Rinsho Ketsueki; 2015 Aug; 56(8):1005-10. PubMed ID: 26345559
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
    Sundararajan S; Kumar A; Korde N; Agarwal A
    Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.
    Pérez-Persona E; Vidriales MB; Mateo G; García-Sanz R; Mateos MV; de Coca AG; Galende J; Martín-Nuñez G; Alonso JM; de Las Heras N; Hernández JM; Martín A; López-Berges C; Orfao A; San Miguel JF
    Blood; 2007 Oct; 110(7):2586-92. PubMed ID: 17576818
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma].
    Jurczyszyn A; Olszewska-Szopa M; Skotnicki AB
    Przegl Lek; 2015; 72(11):642-8. PubMed ID: 27012123
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Smoldering Multiple Myeloma: To Treat or Not to Treat.
    Kapoor P; Rajkumar SV
    Cancer J; 2019; 25(1):65-71. PubMed ID: 30694862
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.
    Bustoros M; Sklavenitis-Pistofidis R; Park J; Redd R; Zhitomirsky B; Dunford AJ; Salem K; Tai YT; Anand S; Mouhieddine TH; Chavda SJ; Boehner C; Elagina L; Neuse CJ; Cha J; Rahmat M; Taylor-Weiner A; Van Allen E; Kumar S; Kastritis E; Leshchiner I; Morgan EA; Laubach J; Casneuf T; Richardson P; Munshi NC; Anderson KC; Trippa L; Aguet F; Stewart C; Dimopoulos MA; Yong K; Bergsagel PL; Manier S; Getz G; Ghobrial IM
    J Clin Oncol; 2020 Jul; 38(21):2380-2389. PubMed ID: 32442065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New approaches to smoldering myeloma.
    Mateos MV; San Miguel JF
    Curr Hematol Malig Rep; 2013 Dec; 8(4):270-6. PubMed ID: 23975678
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis.
    Visram A; Rajkumar SV; Kapoor P; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Dingli D; Kourelis T; Gonsalves W; Warsame R; Muchtar E; Leung N; Baughn LB; Kyle RA; Kumar S
    Blood Cancer J; 2021 Nov; 11(11):186. PubMed ID: 34836942
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.
    González-Calle V; Dávila J; Escalante F; de Coca AG; Aguilera C; López R; Bárez A; Alonso JM; Hernández R; Hernández JM; de la Fuente P; Puig N; Ocio EM; Gutiérrez NC; García-Sanz R; Mateos MV
    Leukemia; 2016 Oct; 30(10):2026-2031. PubMed ID: 27133826
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.
    Jagannath S; Laubach J; Wong E; Stockerl-Goldstein K; Rosenbaum C; Dhodapkar M; Jou YM; Lynch M; Robbins M; Shelat S; Anderson KC; Richardson PG
    Br J Haematol; 2018 Aug; 182(4):495-503. PubMed ID: 29808907
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent Advances in the Management of Smoldering Multiple Myeloma.
    Madhira BR; Konala VM; Adapa S; Naramala S; Ravella PM; Parikh K; Gentile TC
    World J Oncol; 2020 Apr; 11(2):45-54. PubMed ID: 32284772
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.
    Rago A; Grammatico S; Za T; Levi A; Mecarocci S; Siniscalchi A; De Rosa L; Felici S; Bongarzoni V; Piccioni AL; La Verde G; Pisani F; Franceschini L; Paviglianiti AL; Caravita T; Petrucci MT; De Stefano V; Cimino G;
    Cancer; 2012 Nov; 118(22):5544-9. PubMed ID: 22786730
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Role of Early Intervention in High-Risk Smoldering Myeloma.
    Joseph NS; Dhodapkar MV; Lonial S
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-9. PubMed ID: 32182141
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma.
    Markus E; Trestman S; Cohen Y; Angel Y; Sofer Y; Mittelman M; Avivi I; Stern N; Izkhakov E
    BMC Cancer; 2020 May; 20(1):489. PubMed ID: 32473631
    [TBL] [Abstract][Full Text] [Related]  

  • 55. State of the science in smoldering myeloma: Should we be treating in the clinic?
    Hill E; Dew A; Kazandjian D
    Semin Oncol; 2019 Apr; 46(2):112-120. PubMed ID: 31072611
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.
    Kastritis E; Terpos E; Moulopoulos L; Spyropoulou-Vlachou M; Kanellias N; Eleftherakis-Papaiakovou E; Gkotzamanidou M; Migkou M; Gavriatopoulou M; Roussou M; Tasidou A; Dimopoulos MA
    Leukemia; 2013 Apr; 27(4):947-53. PubMed ID: 23183429
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
    Pérez-Persona E; Mateo G; García-Sanz R; Mateos MV; de Las Heras N; de Coca AG; Hernández JM; Galende J; Martín-Nuñez G; Bárez A; Alonso JM; Martín A; López-Berges C; Orfao A; San Miguel JF; Vidriales MB
    Br J Haematol; 2010 Jan; 148(1):110-4. PubMed ID: 19821821
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased microcirculation detected by dynamic contrast-enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma.
    Hillengass J; Ritsch J; Merz M; Wagner B; Kunz C; Hielscher T; Laue H; Bäuerle T; Zechmann CM; Ho AD; Schlemmer HP; Goldschmidt H; Moehler TM; Delorme S
    Br J Haematol; 2016 Jul; 174(1):127-35. PubMed ID: 26991959
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.
    Boyle EM; Deshpande S; Tytarenko R; Ashby C; Wang Y; Bauer MA; Johnson SK; Wardell CP; Thanendrarajan S; Zangari M; Facon T; Dumontet C; Barlogie B; Arbini A; Rustad EH; Maura F; Landgren O; Zhan F; van Rhee F; Schinke C; Davies FE; Morgan GJ; Walker BA
    Nat Commun; 2021 Jan; 12(1):293. PubMed ID: 33436579
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
    J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.